Remuneration committee charter


Board of Directors

Cochlear aims to have a Board of an effective composition, size and commitment to adequately discharge its responsibilities and duties. The Board of Directors currently comprises six independent Non-Executive Directors, including the Chairperson and one Executive Director, the Chief Executive Officer/President.  A majority of the Board must be independent Non-Executive Directors.  The Chairperson must be an independent Non-Executive Director.  The roles of the Chairperson and Chief Executive Officer/President must not be exercised by An independent director is a Non-Executive Director who is not a member of management and who is free of any business or other relationship that could materially interfere with the independent exercise of their judgement.
Responsibilities of the Board
 Oversight of the Company, including its control and accountability systems.  Appointing and removing the Chief Executive Officer/President.  Ratifying the appointment and, where appropriate, the removal of the CFO and the Company  Input into a final approval of management’s development of corporate strategy and  Reviewing and ratifying systems of risk management and internal compliance and control,  Monitoring senior management’s performance and implementation of strategy and ensuring  Approving and monitoring the progress of major capital expenditure, capital management and acquisitions and divestitures and dividend policy.  Approving and monitoring financial and other reporting.
Relationship with Chief Executive Officer/President
The Board has delegated responsibility for day-to-day management of Cochlear to the Chief Executive Officer/President. However, the Chief Executive Officer/President must consult the Chairperson on matters that are sensitive, extraordinary or of a strategic nature.
Board Committees
The Board operates through Committees that are responsible for particular areas of the business. The five existing Committees are the Audit Committee, the Remuneration Committee, the Technology and Innovation Committee, the Medical Science Committee and the Nomination Committee. Each Committee operates in accordance with a written charter or terms of reference. These Committees enable a more detailed involvement of the Board with the business in line with the Committee Charter or terms of reference.
Internal Policies Applicable to Directors
Cochlear has in place the following internal operating policies, which apply personally to Directors:  Non-Executive Directors and Executives Share Ownership Policy The Board is also ultimately responsible for ensuring compliance of Cochlear officers and employees with other Company policies including: CURRENT BOARD MEMBERSHIP
Mrs Yasmin Allen Mr Paul Bell Prof Edward Byrne Mr Andrew Denver Mr Roderic Holliday-Smith Mr Donal O’Dwyer


Technical Information Tretinoin January 2010 Supersedes issue dated February 2009 03_030752e-06/Page 1 of 6 USP, Ph. Eur. Pharma Ingredients & Services 1. Medical indication Tretinoin is a synthetic vitamin A acid derivative used for the treatment of severe forms of acne, such as acne conglobata and acne cystica, which are mostly resistant to other forms of treatment


Canada Product Ingredients This list is compiled based on product information provided by Subway® approved food manufacturers. Every effort is made to keep this information current however it is possible that ingredient changes and substitutions may occur before this list is updated. This list does not include regional or special promotional items as ingredients vary. BREADS

Copyright © 2011-2018 Health Abstracts